Six criteria described in the New Zealand Misuse of Drugs Act and used by the Expert Advisory Committee on Drugs (EACD) for determining the risk of a drug to public health were examined in relation to ethanol, using γ-hydroxybutyric acid (GHB) as a comparator drug. GHB is an ideal candidate for use as a comparator because it is a sedative substance very similar to ethanol and has been previously investigated by the EACD using these six criteria. GHB was subsequently classified as a Class B1 drug under the Misuse of Drugs Act, that is, as a prohibited drug of high risk to public health. The dangerousness level of ethanol was found to be at least similar to that of GHB in this analysis. This highlights a major discrepancy in public policy.
Abu Bakar, AM (2005) Alcohol - the legal drug of abuse. ProfessionalBulletin of the National Poison Centre, Malaysia. PRN8099. http:// www.prn2.usm.my/mainsite/bulletin/1995/prn3.html,accesseddate18/5/07.
2.
Benzer, TI, Cameron, S., Russi, CS (2005) Toxicity, Gamma Hydroxybutyrate. Emergency Medicine Toxicology, eMedicine. Available at http://emedicine.com/emerg/topic848.htmlastupdatedJanuary82007,accesseddate6/5/08.
3.
Bloom, FE (2001) Neurotransmission and the central nervous system, Chapter 12. In: Hardman, JG, Limbird, LE, Gilman, AG (eds), Goodman and Gilman's The Pharmacological Basis of Therapeutics, tenth ed. New York: McGraw-Hill, Medical Publishing Division.
4.
Brown, SA, Tapert, SF, Granholm, E., Delis, DC (2000) Neurocognitive functioning of adolescents: Effects of protracted alcohol use. Alcohol Clin Exp Res24: 164-171.
5.
Connor, J., Broad, J., Jackson, R., Vander Hoorn, S., Rehm, J. (2005a) The burden of death, disease and disability due to alcohol in New Zealand. Wellington, New Zealand: ALAC Occasional Publication No. 23.
6.
Connor, J., Broad, J., Rehm, J., Vander Hoorn, S., Jackson, R. (2005b) The burden of death, disease and disability due to alcohol in New Zealand. N Z Med J118: 1-12. http://www.nzma.org.nz/journal/118-1213/1412/,accesseddate6/5/08 .
7.
Crome, I., Ghodse, H., Gilvarry, E McArdle (2004) Young People and Substance Misuse. London: Royal College of Psychiatrists.
8.
DeBellis, R., Smith, BS, Choi, S., Malloy, M. (2005) Management of delirium tremens. J Intensive Care Med20: 164-173.
9.
De Bonnaire, C., McMillen, P., Lafatelis, E. (2004). The way we drink: the current attitudes & behaviours of New Zealanders (aged 12 plus) towards drinking alcohol. Wellington: Alcohol Advisory Council of New Zealand .
10.
Di Castelnuovo, A., Costanzo, S., Bagnardi, V., Donati, MB, Iacoviello, L., de Gaetano, G. (2006) Alcohol dosing and total mortality in men and women: an updated meta-analysis of 34 prospective studies. Arch Intern Med166: 2437-2445.
11.
Dyer, JE, Roth, B., Hyma, BA (2001) Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med37: 147-153.
12.
EACD (Expert Advisory Committee on Drugs) ( 2001) Gammahydroxybutryic acid and related substances ("Fantasy"). Report released December 2001. http://www.moh.govt.nz/moh.nsf/pagescm/569/$File/eacdfantasy.pdf,accesseddate6/5/08.
13.
Elliot, SP (2003) Gamma hydroxybutyric acid (GHB) concentrations in humans and factors affecting endogenous production. Forensic Sci Int133: 9-16.
14.
EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) (2001) Report on the risk assessment of GHB in the framework of the joint action on new synthetic drugs, http://www.emcdda.europa.eu/html.cfm/index431EN.html,accesseddate6/5/08.
15.
Fleming, M., Mihic, SJ, Harris, RA (2001) Ethanol, Chapter 18. In: Hardman, JG, Limbird, LE, Gilman, AG (eds), Goodman and Gilman's The Pharmacological Basis of Therapeutics, tenth ed. New York: McGraw-Hill, Medical Publishing Division.
16.
Gallimberti, L., Ferri, M., Ferrara, SD, Fadda, F., Gessa, GL (1992) Gamma-hydroxybutyric acid in the treatment of alcohol dependence: A double-blind study. Alcohol Clin Exp Res16: 673-676.
17.
Goldberg, DM, Hahn, SE, Parkes, JG (1995) Beyond alcohol: beverage consumption and cardiovascular mortality. Clin Chim Acta237: 155-187.
18.
Gonzalez, A., Nutt, DJ (2005) Gamma hydroxyl butyrate abuse and dependency. J Psychopharmacol19: 195-204.
19.
Gossop, M. (2006) Classification of illegal and harmful drugs. BMJ333: 272-273.
20.
House of Commons Science and Technology Select Committee (2006) Drug Classification: Making a Hash of It? 5th Report of Session 2005-2006, HC 1031.
21.
Inter-Departmental Working Group (1995) Sensible Drinking. London: Department of Health.
Leone, MA, Avanzi, GC, Lo Iacono, A., Vigna-Taglianti, F., Faggiano, F. (2006) Gamma-hydroxybutyrate (GHB) for prevention and treatment of alcohol withdrawal (Protocol). Cochrane Database Syst Rev Issue4, Art. No: CD006266. DOI: 10.1002/14651858.CD006266.
25.
Li, J., Stokes, SA, Woeckener, A. (1998) A tale of novel intoxication: A review of the effects of gamma-hydroxybutyric acid with recommendations for management. Ann Emerg Med31: 729-736.
26.
MacDonald, R., Das, A. (2006) UK classification of drugs of abuse: an un-evidence-based mess. Lancet368: 559-561.
Mamelak, M., Scharf, M., Woods, M. (1986) Treatment of narcolepsy with gamma-hydroxybutyrate: a review of clinical and sleep laboratory findings. Sleep9: 285-289.
29.
McIntosh, AS (2005) Rugby injuries. Med Sport Sci49: 120-139.
30.
Mental Health Foundation (2006) Cheers? Understanding the relationship between alcohol and mental health. London: The Mental Health Foundation. http://www.mentalhealth.org.uk/campaigns/mhaw/alcohol,accesseddate6/5/08.
31.
Merrick, J., Merrick, E., Morad, M., Kandel, I. (2006) Fetal alcohol syndrome and its long-term effects . Minerva Pediatr58: 211-218.
32.
Murray, CJ, Lopez, AD (1997) Global mortality, disability and the contribution of risk factors: Global Burden of Disease Study. Lancet349: 1436-1442.
33.
New Zealand Parliament (NZP) (1975). Misuse of Drugs Act (1975) No 116 (as at 01 April 2008), Public Act . http://www.legislation.govt.nz/act/public/1975/0116/latest/DLM436101.html?search=ts_act_Misuse+of+Drugs+Act+(1975)&sr=1, accessed date 6/5/08.
34.
New Zealand Parliament (NZP) (1989). Sale of Liquor Act (1989) No 63 (as at 03 September 2007), Public Act. http://www.legislation.govt.nz/act/public/1989/0063/latest/DLM165116.html?search=ts_act_Sale+of+Liquor+Act&sr=1, accessed date 6/5/08.
35.
Nutt, D. (2006) A tale of two Es. J Psychopharmacol20: 315-317.
36.
Nutt, D., King, LA, Saulsbury, W., Blakemore, C. (2007) Development of a rational scale to assess the harm of drug of potential misuse. Lancet369: 1047-1053.
37.
Oakley-Browne, MA, Wells, JE, Scott, KM, McGee, MA (2006) Lifetime prevalence and projected lifetime risk of DSM-IV disorders in Te Rau Hinengaro: The New Zealand Mental Health Survey . Aust N Z J Psychiatry40: 865-874.
38.
O'Dowd, A. (2006) Tobacco and alcohol should be classed as dangerous drugs. BMJ333: 275.
39.
O'Hagan, J., Robinson, G., Whiteside, E. (1993) Alcohol and Drug Problems: Handbook for Health Professionals. New Zealand: Alcohol Advisory Council of New Zealand, Wellington.
40.
Pappas, SC, Silverman, M. (1982) Treatment of methanol poisoning with ethanol and hemodialysis. Can Med Assoc J126: 1391-1394.
41.
Poldrugo, F., Addolorato, G. (1999) The role of gamma-hydroxybutyric acid in the treatment of alcoholism: From animal to clinical studies. Alcohol Alcohol34: 15-24.
42.
Room, R. (2006) The dangerousness of drugs. Addiction101: 166-168.
43.
Room, R., Babor, T., Rehm, J. (2005) Alcohol and public health. Lancet365: 519-530.
44.
Royal College of Psychiatrists (2005) Alcohol: Our favourite drug. London: Mental Health Information, Leaflets Department, The Royal College of Psychiatrists . http://www.rcpsych.ac.uk/mentalhealthinformation/mentalhealthproblems/alcoholanddrugs/alcoholourfavouritedrug.aspx , accessed date 6/5/08.
45.
Schuckit, MA (1995) Drug and Alcohol Abuse: A Clinical Guide to Diagnosis and Treatment, fourth ed. New York: Plenum Publishing Corporation.
46.
Schuckit, MA, Irwin, M. (1988) Diagnosis of alcoholism. Med Clin North Am72: 1133-1153.
47.
Scott-Ham, M., Burton, FC (2005) Toxicological findings in cases of alleged drug-facilitated sexual assault in the United Kingdom over a 3-year period. J Forensic Med12: 175-186.
48.
Shannon, M., Quang, LS (2000) Gamma-hydroxybutyrate, gamma-butyrolactone, and 1,4-butanediol: a case report and review of the literature. Pediatr Emerg Care16: 435-440.
49.
Smith, LO (2006) Alpine climbing: Injuries and illness. Phys Med Rehabil Clin N Am17: 633-644.
50.
Vickers, MD (1969) Gammahydroxybutyric acid. Int Anesthesiol Clin7: 75-89.
51.
Wells, JE, Oakley-Browne, MA, Scott, KM, McGee, MA, Baxter, J., Kokaua, J. (2006) Prevalence, interference with life and severity of 12 month DSM-IV disorders in Te Rau Hinengaro: The New Zealand Mental Health Survey. Aust N Z J Psychiatry40: 845-854.
52.
Young, R., Feeney, G. (2002) Why do people use drugs? Chapter 2. In: Hulse, G, White, J, Cape, G (eds), Management of Alcohol and Drug Problems. Melbourne: Oxford University Press.
53.
Zvosec, DL, Smith, SW, McCutcheon, JR, Spillane, J., Hall, BJ, Peacock, EA (2001) Adverse events, including death, associated with the use of 1, 4 butanediol. N Engl J Med344: 87-94.
